# Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

> **NCT04784247** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 52 (estimated)

## Conditions studied

- Advanced Sarcoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04784247
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-18
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- Merck Sharp & Dohme LLC
- Parker Institute for Cancer Immunotherapy

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784247, "Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04784247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*